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OriginalClinicalScienceçGeneralSurvival Benefit in Renal Transplantation Despite
High Comorbidity
Vibeke Rømming Sørensen, MD, PhD,1 James Heaf, MD, DMSc,2 Sonja Wehberg, MSc, PhD,3,4
and Søren Schwartz Sørensen, MD, DMSc1
Background. The age and degree of comorbidity among transplant candidates is increasing. Knowledge of survival benefit in
relation to recipient age and comorbidity is important, considering the scarcity of organs available for transplantation. The aim of
the present study was to analyze the chances and survival benefit of transplantation among patients in different age groups
and with different degrees of comorbidity score at the time of entering the waiting list.Methods. Data from the Danish Ne-
phrology Registry and Scandiatransplant were merged. Charlson Comorbidity Index scores were derived from the National
Danish Admissions Registry. Study period is from January 1, 1995, to December 31, 2011. A multistate model was used to an-
alyze the chance of having a renal transplantation and the effect of transplantation in different patients groups. Results. Pa-
tients older than 65 years and patients with high comorbidity score had a decreased chance of being transplanted. However,
if patients older than 65 years were transplanted with deceased donor, the mortality risk was reduced by 55% (hazard rate,
0.45 (0.26-0.75). In patients with a comorbidity score of 5 or greater, receiving a deceased donor transplant reduced the mor-
tality risk by 72% (hazard rate, 0.28 (0.20-0.39). The overall survival benefit was 62% versus 70% in deceased versus living do-
nor transplanted patients. Conclusions. Poor health and old age reduced the chance of being transplanted. However,
patients older than 65 years and patients with high comorbidity still had a survival benefit from renal transplantation.
(Transplantation 2016;100: 2160–2167)Renal transplantation is considered the best renal replace-ment treatment for patients with end-stage renal disease
(ESRD).1,2 Although no prospective studies, randomizing
patients to either treatment with dialysis or renal transplan-
tation have been performed, several retrospective registry
studies have compared survival among waiting list (WL)
patients to transplanted patients and found that even after
correction for the difference in age, sex, and renal diagnosis,Received 20 April 2015. Revision received 27 September 2015.
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2160 www.transplantjournal.comthe mortality in WL patients is significantly higher than in
transplanted patients.1-10 The main problem in retrospective
registry studies is the possibility of selection bias. Although
all transplantation candidates undergo the same evaluation
before being accepted on the WL, it is not known if the pa-
tients who never receive a transplant were actually as healthy
as the patients who were transplanted. In general, large regis-
try studies have no or very limited information on comorbid-
ity in transplant candidates.11,12 The Danish Nephrology
Registry (DNR) in combination with the Scandiatransplant
registry contains detailed data concerning all ESRD patients,
including comorbidity data derived from the Danish Na-
tional Patient Register, which records all hospital and outpa-
tient discharge diagnoses. Comorbidity data are available
both at time of WL entry and transplantation.
Patients older than 60 years are the fastest-growing group
of patients with ESRD.13 In Denmark, as in many other
countries, there has been a tendency to accept more patients
on the WL regardless of age and comorbidity. Because of
the disparity between the supply and demand for kidney
transplantation, some of the patients on the WL die while
they are waiting for a kidney, and others are permanently
withdrawn from the WL due to progression of comorbidity.
The allocation of kidneys toward patients who may benefit
the most is thus an increasingly important issue.
The aims of this study were therefore to use data regarding
comorbidity at the time of entering the WL to analyze the ef-
fect of health status on the chance of being transplanted, and
to analyze the effect of transplantation on mortality in gen-
eral and in subgroups according to age and comorbidity.
Finally, an analysis of causes of death was performed.Transplantation ■ October 2016 ■ Volume 100 ■ Number 10
FIGURE 2. Illustration of model fit. Cumulative hazards for mortality
in patients remaining on the waiting list compared to transplanted pa-
tients based on stratified versus univariate Cox regression (common
baseline).
© 2015 Wolters Kluwer Sørensen et al 2161MATERIALS AND METHODS
Datawere derived from theDNR,which has been compre-
hensive since 1990. The registry forms the basis of the Danish
section of the European Renal Association-European Dialy-
sis and Transplantation Association registry. The following
data were recorded: date of birth, sex, renal diagnosis using
standard European Renal Association-European Dialysis
and Transplantation Association terminology, date of ESRD,
treatment modality (haemodialysis, peritoneal dialysis or
transplantation), date of change of treatment modality,
follow-up date (death, lost to follow-up), and cause of death.
The Scandiatransplant database (SCTP) was reorganized
in 1994. Since then, all Danish patients placed on the WL
or receiving living or deceased donor transplantation
(DDT) have been registered. The following data from SCTP
were recorded: date of birth, date of entry on the WL, with-
drawal date, and withdrawal cause (transplantation, death,
or permanent withdrawal). Withdrawal from the WL was
not studied in this investigation. Data from SCTP were
merged with data from DNR. Patients, who waited for their
first renal transplant, and whose first registration on the SCTP
WL was between January 1, 1995, and December 31, 2011,
were included. All patients were followed up until death, emi-
gration or December 31, 2011. TheWL patients who received
a transplant in a foreign country were included. Information
on donor age, sex, body mass index (BMI), and blood type
was also recorded.
The Charlson Comorbidity Index (CCI) scores were de-
rived from the Danish National Patient Register, which has
recorded all hospital discharge diagnoses since 1977.14,15
The CCI is validated in patients with ESRD patients and is
linked to the Danish Registry.16 The CCI scores were available
for the time of first WL registration and include 19 diagnoses
associated with increased risk of death.17 All patients were
automatically assigned 2 CCI points due to renal failure.
In Denmark, patients younger than 18 years have trans-
plantation priority, meaning that they are offered the first
suitable kidney available. Policies concerning adult organ al-
location differ between the transplantation centres, including
such factors as best tissue type match, best age match, or WL
duration. In a national report from 2007, there was no differ-
ence in waiting time for adults relative to age.18
Statistical Analysis
We analyzed data by using a multistate model including
both DDT and living donor transplantation (LDT). At any
given time after the first WL entry, a patient is in 1 of 3 main
stages: (1) still on theWL, (2) transplanted with a deceased or
a living donor, or (3) dead. The transition between stages is
illustrated in Figure 1. In our analyses, withdrawal from theFIGURE 1. Multi state model DDT, LDT.WL, graft failure (meaning that the patient returned to dialy-
sis treatment), or repeat transplants were ignored.
First, we analyzed the effects of baseline (fixed) covariates
on time to transplantation (meaning the chance of being
transplanted), where the cause-specific hazard is modelled
by Cox regression (Figure 1, transition 1- to >2). Second,
we analyzed the effects of baseline (fixed) covariates as well
as the effect of time-dependent transplantation status on
mortality by Cox regression (transition 1 to >3 and 2 to >3
combined). Figure 2 illustrates the model fit by plotting cu-
mulative hazards based on a (univariate) Cox model with
common baseline hazard for both LDT and DDT status
against separate cumulative hazard estimates from a strati-
fied Cox mode without covariates (for transition 1 to >3, pa-
tients are censored at time of transplantation; for transition 2
to >3, patients enter at time of transplantation [delayed en-
try]). Additionally, we explored interactions between trans-
plantation status and age category, comorbid category, and
cohort separately in the multivariable setting.
Third, we expanded the multistate model to incorporate
different causes of death divided into 5 categories: infection,
cancer, heart disease, vascular disease, and other cause. Last,
we analyzed the effects of fixed covariates, including donor
information, on mortality after transplantation by Cox re-
gression (transition 2 to >3 alone).
RESULTS
A total of 3174 patients were included in the study, and
2349 of these patients had a first renal transplant during
the study period. Transplantation with a deceased donor
was performed in 1535 patients, including 1 transplantation
abroad, whereas 814 patients received a transplant from a
living donor, including 19 transplantations abroad. Only
1 patient was lost to follow-up due to emigration.
Patient Characteristics at Baseline
The distribution of patient baseline characteristics at the
time of entering the WL, after 1, 5, and 10 years, and in
transplanted versus never transplanted/WL patients is shown
in Table 1. The number of patients entering the WL per year
increased after 2002. A total of 37% had been on dialysis for
2162 Transplantation ■ October 2016 ■ Volume 100 ■ Number 10 www.transplantjournal.commore than 1 year before being listed for transplantation. Ap-
proximately half of the patients had no comorbidity besides
their renal failure, whereas 22% had a CCI index of 5 or
more. The percentage of patients older than 65 years at the
time of entering the WL, increased from 2% during the first
period to 8% during the last period (data not shown). The
patients in theWL group were older, spend longer time in di-
alysis before entering the WL, and had more comorbidity at
the time of entering the WL compared to the transplanted
patients. Figure 3 shows the patient status after 1, 2, 3, 4, 5,
and 10 years. Nearly half of the patients had a renal trans-
plant within the first year after entering the WL, whereasTABLE 1.
Patient characteristics at the time of entering the waiting list and
Factor Baseline TX after 1 ya TX after 5 y
3174 (100) 1544 (49) 2258 (71)
LRRT 681 (44) 799 (35)
DDRT 863 (56) 1459 (65)
Cohort
1995-1998 706 (22) 359 (51) 521 (74)
1999-2002 689 (22) 297 (43) 497 (72)
2003-2006 755 (24) 344 (46) 563 (75)
2007-2011 1024 (32) 544 (53) 677 (66)
Age, y
0-17 156 (5) 137 (88) 151 (97)
18-44 1272 (40) 692 (54) 987 (78)
45-54 801 (25) 359 (45) 561 (70)
55-64 777 (24) 291 (37) 464 (60)
≥65 168 (5) 65 (39) 95 (57)
Female sex 1211 (38) 585 (48) 864 (71)
Renal diagnosis
Small 570 (18) 276 (48) 396 (69)
GN 761 (24) 415 (55) 578 (76)
CIN 322 (10) 161 (50) 222 (69)
Polycystic 392 (12) 194 (49) 306 (78)
Hypertensive 283 (9) 111 (39) 174 (61)
DM (type 1 and type 2) 553 (17) 232 (42) 360 (65)
Systemic GN 107 (3) 58 (54) 80 (75)
Vasculitis 36 (1) 15 (42) 29 (81)
HUS/TTP 35 (1) 22 (63) 27 (77)
Other 115 (4) 60 (52) 86 (75)
Time in dialysis before WL, y
0 661 (21) 425 (64) 552 (84)
>0 to <1 1350 (43) 663 (49) 1023 (76)
1 to <2 617 (19) 271 (44) 403 (65)
2 to <3 224 (7) 88 (39) 135 (60)
3 to <5 162 (5) 71 (44) 101 (62)
≥5 160 (5) 26 (16) 44 (28)
CCI
2 1618 (51) 874 (54) 1257 (78)
3-4 843 (27) 391 (46) 572 (68)
≥5 713 (22) 279 (39) 429 (60)
Blood group
O 1328 (42) 567 (43) 904 (68)
A 1340 (42) 760 (57) 1019 (76)
B 360 (11) 123 (34) 216 (60)
AB 146 (5) 94 (64) 119 (82)
a Percentages after 1, 5, and 10 years are calculated based on all patients in the respective group, regar
b Group status is not known at baseline.
EOS indicates end of study; TX, transplantation.71% and 74% had been transplanted within 5 and 10 years,
respectively.
The Chance of Receiving a Renal Transplant
Table 2 shows the relationship between the effects of base-
line (fixed) covariates and the chance of renal transplanta-
tion, defined as time to transplantation. Dividing the
patients into 4 cohorts according to the year of entering the
WL, the table shows that the chance of being transplanted
with a deceased donor did not change during the study pe-
riod, whereas the chance of being transplanted with a living
donor increased significantly in the third (2003-2006) andstatus after 1, 5, and 10 y and at EOS
TX after 10 y TX before EOS/deathb Still WL at EOS/deathb
2340 (74) 2349 (100) 825 (100)
810 (35) 814 (35)
1530 (65) 1535 (65)
541 (77) 548 (23) 158 (19)
532 (77) 534 (23) 155 (19)
590 (78) 590 (25) 165 (20)
677 (66) 677 (29) 347 (42)
151 (97) 152 (6) 4 (0)
1029 (81) 1036 (44) 236 (29)
589 (74) 590 (25) 211 (26)
475 (61) 475 (20) 302 (37)
96 (57) 96 (4) 72 (9)
895 (74) 899 (38) 312 (38)
408 (72) 408 (17) 162 (20)
601 (79) 605 (26) 156 (19)
230 (71) 230 (10) 92 (11)
318 (81) 320 (14) 72 (9)
185 (65) 185 (8) 98 (12)
369 (67) 370 (16) 183 (22)
82 (77) 82 (3) 25 (3)
29 (81) 29 (1) 7 (1)
28 (80) 29 (1) 6 (1)
90 (78) 91 (4) 24 (3)
574 (87) 576 (25) 85 (10)
1059 (78) 1063 (45) 287 (35)
422 (68) 423 (18) 194 (24)
138 (62) 138 (6) 86 (10)
103 (64) 104 (4) 58 (7)
44 (28) 45 (2) 115 (14)
1307 (81) 1313 (56) 305 (37)
592 (70) 594 (25) 249 (30)
441 (62) 442 (19) 271 (33)
947 (71) 953 (41) 375 (45)
1039 (78) 1042 (44) 298 (36)
234 (65) 234 (10) 126 (15)
120 (82) 120 (5) 26 (3)
dless of their time at risk.
FIGURE 3. Percentage of patients who were transplanted 1 to 5
and 10 years after entering the waiting list (based on the 3174 patients
included, regardless of their time of risk). TABLE 2.
Time to transplantation (chance of having a transplantation)
Factor DDT: HR (CI) LDT: HR (CI)
Cohort
1995-1998 1 (ref ) 1 (ref )
1999-2002 0.95 (0.82-1.1) 0.94 (0.76-1.16)
2003-2006 0.91 (0.79-1.06) 1.27 (1.04-1.54)
2007-2011 1.04 (0.89-1.22) 1.97 (1.65-2.36)
Age, y
0-17 2.52 (1.84-3.47) 1.84 (1.52-2.23)
18- 1 (ref ) 1 (ref )
45 0.99 (0.87-1.12) 0.46 (0.38-0.55)
55 0.84 (0.73-0.96) 0.35 (0.28-0.43)
≥65 0.73 (0.56-0.95) 0.33 (0.21-0.5)
Female sex 0.94 (0.84-1.04) 0.87 (0.76-0.99)
Renal diagnosis
Small 0.94 (0.79-1.1) 0.68 (0.56-0.82)
GN 1 (ref ) 1 (ref )
CIN 0.98 (0.82-1.19) 0.68 (0.54-0.85)
Polycystic 1.1 (0.92-1.31) 0.68 (0.54-0.86)
Hypertensive 0.83 (0.68-1.01) 0.73 (0.56-0.95)
DM (type 1 and type 2) 1.05 (0.83-1.32) 0.66 (0.49-0.89)
Systemic GN 0.98 (0.7-1.38) 1.31 (0.95-1.82)
Vasculitis 1.1 (0.67-1.81) 1.15 (0.66-2.03)
HUS/TTP 1.15 (0.73-1.83) 0.87 (0.48-1.56)
Other 0.92 (0.69-1.23) 0.71 (0.51-1)
Time in dialysis before WL, y
0 1.16 (1.01-1.32) 1.62 (1.41-1.87)
>0 to <1 1 (ref ) 1 (ref )
1 to <2 0.94 (0.82-1.07) 0.71 (0.58-0.87)
2 to <3 0.86 (0.69-1.07) 0.63 (0.45-0.9)
3 to <5 0.86 (0.64-1.16) 0.58 (0.39-0.86)
≥5 0.26 (0.18-0.37) 0.12 (0.06-0.25)
CCI
2 1 (ref ) 1 (ref )
3-4 0.89 (0.78-1.01) 0.89 (0.75-1.06)
> = 5 0.74 (0.6-0.91) 0.91 (0.7-1.19)
Blood group
O 1 (ref ) 1 (ref )
A 1.43 (1.28-1.6) 1.34 (1.17-1.53)
B 0.7 (0.59-0.83) 1 (0.8-1.24)
AB 2.5 (2-3.13) 1.22 (0.88-1.7)
HR and corresponding 95% confidence intervals (CI) based on multivariate cause-specific Cox
regression.
© 2015 Wolters Kluwer Sørensen et al 2163fourth (2007-2011) cohorts. Patients younger than 18 years
when entering the WL were more often transplanted with a
living donor. In addition, they had a significantly higher
chance of DDT, in accordance with national allocation pol-
icy. Patients older than 55 years had a significantly decreased
transplantation chance compared with patients 18 to
44 years. There was a highly significantly decreased LDT
chance with increasing age. Patients who were listed for
transplantation before ESRD had a significantly better DDT
chance comparedwith patientswhowere listed during the first
year after ESRD, whereas patients who had been on dialysis
for more than 5 years had a 74% decreased chance of DDT
compared to patients who were listed within the first year.
The DDT chance was significantly lower in patients with a
CCI of 5 or more, but this was not the case for LDT. Patients
with the blood type B had significantly lower chance of DDT,
whereas blood type did not matter in LDT.
Survival and Associated Variables
The unadjusted cumulative hazard rate (HR) for death in
patients remaining on the WL compared with transplanted
patients is shown in Figure 2, indicating a satisfactory model
fit. The cumulative hazard was highly increased in patients
who were not transplanted. A multivariable mortality analy-
sis corrected for cohort, age, sex, renal diagnosis, time on di-
alysis before entering the WL, CCI, is shown in Table 3.
Patients who received either LDTorDDT had a highly signif-
icant lower mortality risk with a survival benefit of 70% in
LDTand 62% in DDT. The overall prognosis for all patients
improved over time with a 44% mortality risk reduction in
the period 2007 to 2011 compared with 1995 to 1998. This
HR reduction was independent of transplantation status, be-
cause adding an interaction between transplantation status
and cohort to the multivariate model did not lead to statisti-
cally significant model improvement (Likelihood ratio test:
P = 0.53). Mortality risk in the 2349 patients who were
transplanted during the study is shown in Table 4. Neither
donor age, donor type (DDT/LDT) nor time on the WL be-
fore transplantation affected recipient mortality risk. How-
ever, donor BMI higher than 25 or lower than 18.5 was
related to a significantly poorer recipient survival. Also, co-
hort, recipient age, time on dialysis before WL entry, diabe-
tes, and CCI all significantly affected the mortality risk.Age and Comorbidity
Adding an interaction of age categorywith transplantation
status to the model resulted in borderline model improve-
ment (Likelihood ratio test: P = 0.057). The corresponding
HRs are shown in Figure 4. Using the transplant status 0
(WL) and age group 18 to 44 years as reference, the figure
shows an increasing mortality with increasing age, but also
a significantly decreased mortality in patients who changed
transplant status from 0 (WL) to either 1 or 2 ( DDT or
LDT). Changing the reference category to patients older than
65 years, and in the WL group, we found that the HR for
DDT was 0.45 (0.26-0.75, 95% CI) and 0.58 (0.21-1.60,
95% CI) for LDT.
Mortality risk increased significantly with increasing CCI
value. The mortality risk of the 22% of the patients, who
TABLE 3.
Mortality (time to death) in 3174 patients after entering the






LDT 0.16 (0.12-0.2) 0.3 (0.23-0.39)
DDT 0.31 (0.27-0.37) 0.38 (0.32-0.45)
Cohort
1995-1998 1 (ref ) 1 (ref )
1999-2002 0.85 (0.71-1) 0.68 (0.57-0.81)
2003-2006 0.8 (0.66-0.98) 0.63 (0.51-0.77)
2007-2011 0.71 (0.54-0.94) 0.56 (0.42-0.75)
Age, y
0-17 0.39 (0.2-0.75) 0.74 (0.37-1.46)
18-44 1 (ref ) 1 (ref )
45-54 2.46 (2.05-2.96) 2.24 (1.85-2.71)
55-64 3.76 (3.14-4.51) 3.18 (2.62-3.86)
≥65 4.17 (3.14-5.52) 3.6 (2.64-4.91)
Female sex 0.92 (0.8-1.06) 0.95 (0.82-1.1)
Renal diagnosis
Small 1.62 (1.29-2.03) 1.33 (1.05-1.67)
GN 1 (ref ) 1 (ref )
CIN 1.55 (1.19-2.03) 1.53 (1.17-1.99)
Polycystic 1.04 (0.79-1.36) 0.98 (0.74-1.28)
Hypertensive 1.75 (1.33-2.29) 1.41 (1.09-1.82)
DM (type 1 and type 2) 2.57 (2.09-3.15) 1.6 (1.24-2.07)
Systemic GN 1.37 (0.91-2.07) 1.08 (0.7-1.67)
Vasculitis 0.94 (0.41-2.16) 0.7 (0.31-1.59)
HUS/TTP 0.77 (0.35-1.7) 1.14 (0.52-2.53)
Other 0.86 (0.54-1.36) 0.9 (0.54-1.51)
Time in dialysis before WL, y
0 0.74 (0.6-0.91) 0.9 (0.74-1.11)
>0 to <1 1 (ref ) 1 (ref )
1 to <2 1.56 (1.3-1.87) 1.35 (1.12-1.63)
2 to <3 2.16 (1.7-2.75) 1.43 (1.11-1.83)
3 to <5 1.57 (1.14-2.16) 1.31 (0.95-1.81)
≥5 2.89 (2.25-3.71) 1.8 (1.34-2.43)
CCI
2 1 (ref ) 1 (ref )
3-4 2.22 (1.88-2.62) 1.78 (1.49-2.13)
≥5 3.2 (2.71-3.77) 2.28 (1.8-2.89)
Blood group
O 1 (ref ) 1 (ref )
A 0.95 (0.82-1.1) 1.02 (0.88-1.19)
B 1.16 (0.94-1.43) 1.05 (0.85-1.29)
AB 1.07 (0.76-1.51) 0.99 (0.66-1.48)
HR and corresponding 95% confidence intervals (CI) based on Cox regression.
2164 Transplantation ■ October 2016 ■ Volume 100 ■ Number 10 www.transplantjournal.comhad a CCI of 5 or more at WL entry, was more than 100%
higher than patientswith a CCI of 2. The addition of an inter-
action between transplantation status and CCI category im-
proved the model significantly (Likelihood ratio test:
P = 0.02), implying a separate effect of transplantation status
for each CCI group (Figure 5). Changing reference category
to patients with CCI of 5 or greater and transplant status 0
(WL), we found that the HR for DDT was 0.28 (0.20-0.39)
and for LDT 0.33 (0.21-0.52).
Causes of Death
A total of 832 (26%) patients died during the study period.
The causes of death were categorised in 5 main groups. Thedistribution in WL, DDT, and LDT patients is shown in
Figure 6. The increased mortality seen in WL patients was
mainly due to cardiovascular diseases and infection. The ab-
solute risk of dying because of cancer was not significantly
different in the 3 groups, although cancer represented a
higher percentage of deaths among transplanted patients
compared to WL patients on dialysis.DISCUSSION
This epidemiological study of renal transplant candidates
in Denmark, combining data from several national registries,
demonstrated a highly significant survival benefit of renal
transplantation, even in patients older than 65 years and in
patients with high comorbidity score. This is in accordance
with several other retrospective register studies that have re-
ported similarly improved survival among transplanted pa-
tients. In a systematic review of 110 studies, including a
total of more than 1.9 million patients, comparing outcomes
in kidney transplantation with dialysis, Tonelli et al3 found
that kidney transplantation was associated with substantial
reductions in the risk of mortality and cardiovascular events.
The review also reported an increasing relative survival
benefit of transplantation over time, with a 66% mortality
reduction compared with dialysis in 1985 and 83% reduc-
tion in 2005. However, most studies did not include any
information on comorbidity and many studies included
dialysis patients not listed for transplantation in the com-
parator group.
Thus, renal transplantation is considered the preferred
treatment for patients with ESRD, but although WL candi-
dates are evaluated by the same pretransplant work-up pro-
gram before entering the WL, the present study showed
that patients not receiving a renal transplant had significantly
more comorbidity, older age, and longer time from ESRD to
WL entry. Some of the patients who remain on the WLs are
probably not equally good candidates for transplantation
and may not have the same chance of being transplanted.
By using information on comorbidity, we aimed to eliminate
some of the assumed selection bias.
We have not included data on temporary withdrawal, but
it is likely that patients with high comorbidity score are more
often temporarily unsuitable for transplantation due to infec-
tion or other complications, although this may not always be
registered in the transplant database. However, if the patients
with high comorbidity index were transplanted, there was a
highly decreasedmortality. In the analysis of the survival ben-
efit of transplantation in the different age groups, we found
significantly improved survival even in patients older than
65 years who were transplanted with a deceased donor, but
only an insignificantly lower HR for LDT. This lack of signif-
icancemay be due to lack of power, since only a limited num-
ber of patients older than 65 years received a LDT.
In this study, the percentage of patients older than 65 years
when entering the WL increased from 2% to 8% during the
17-year study period, whereas more than 50% of all new pa-
tients with ESRD in Denmark in 2011 were older than
65 years. In a study of more than 50 000 patients older than
60 years when listed for renal transplantation in the United
States, Schold et al19 estimated the mortality risk within
5 years and compared that to the chance of transplantation
within 5 years. The study concluded that among patients
TABLE 4.
Mortality (time from TX to death) in 2349 patients who had
a renal transplant
Factor N = 2349 (100%) Multivariate model HR (CI)
Donor type
LDT (baseline) 814 (35) 1 (ref )
DDT 1535 (65) 1.39 (0.79-2.46)
Time on WL (before TX), y
0-0.5 1167 (50) 1 (ref )
0.5-1 377 (16) 1.3 (0.97-1.74)
1-2 374 (16) 1.13 (0.85-1.51)
2-3 177 (8) 1.36 (0.93-2)
3-4 101 (4) 1.14 (0.71-1.85)
4-5 62 (3) 1.43 (0.74-2.76)
>5 91 (4) 1.36 (0.69-2.68)
Cohort
1995-1998 548 (23) 1 (ref )
1999-2002 534 (23) 0.74 (0.58-0.95)
2003-2006 590 (25) 0.57 (0.41-0.8)
2007-2011 677 (29) 0.35 (0.2-0.6)
Age, y
0-17 152 (6) 0.81 (0.36-1.8)
18-44 1036 (44) 1 (ref )
45-54 590 (25) 2.64 (2.03-3.45)
55-64 475 (20) 4.07 (3.09-5.34)
≥65 96 (4) 5.03 (3.06-8.26)
Female sex 899 (38) 0.94 (0.75-1.16)
Renal diagnosis
Small 408 (17) 1.39 (1-1.94)
GN 605 (26) 1 (ref )
CIN 230 (10) 1.31 (0.87-1.98)
Polycystic 320 (14) 1.04 (0.71-1.53)
Hypertensive 185 (8) 1.49 (1.02-2.19)
DM (type 1 and type 2) 370 (16) 1.73 (1.17-2.55)
Systemic GN 82 (3) 1 (0.56-1.81)
Vasculitis 29 (1) 0.48 (0.14-1.66)
HUS/TTP 29 (1) 1.82 (0.75-4.41)
Other 91 (4) 1.24 (0.68-2.26)
Time in dialysis before WL, y
0 576 (25) 0.95 (0.72-1.26)
>0 to <1 1063 (45) 1 (ref )
1 to <2 423 (18) 1.42 (1.09-1.86)
2 to <3 138 (6) 1.74 (1.22-2.49)
3 to <5 104 (4) 1.41 (0.88-2.24)
≥5 45 (2) 3.91 (2-7.66)
CCI
2 1313 (56) 1 (ref )
3-4 594 (25) 1.91 (1.49-2.46)
≥5 442 (19) 1.99 (1.4-2.83)
Blood group
O 953 (41) 1 (ref )
A 1042 (44) 0.97 (0.44-2.14)
B 234 (10) 1.93 (0.87-4.26)
AB 120 (5) 1.58 (0.45-5.47)
Donor Age
0-17 85 (4) 0.46 (0.21-1.03)
18-44 795 (34) 1 (ref )
45-54 647 (28) 1.21 (0.94-1.57)
55-64 567 (24) 1.16 (0.88-1.53)
≥65 255 (11) 1.33 (0.93-1.89)
TABLE 4. (Continued)
Factor N = 2349 (100%) Multivariate model HR (CI)
Donor BMI, kg/m2
Underweight: <18.5 50 (2) 2.65 (1.14-6.13)
Normal: 18.5-24.9 1032 (44) 1 (ref )
Pre-obese: 25.0-29.9 571 (24) 1.33 (1.04-1.7)
Obese I + II: 30.0-39.9 210 (9) 1.71 (1.18-2.49)
Missing 486 (21) 1.27 (0.74-2.18)
Donor blood group
O 1093 (47) 1 (ref )
A 956 (41) 0.93 (0.42-2.03)
B 214 (9) 0.62 (0.27-1.42)
AB 86 (4) 0.68 (0.18-2.56)
Donor female sex 1194 (51) 1.12 (0.91-1.38)
Hazard ratios (HR) and corresponding 95% confidence intervals (CI) based on Cox regression. Only
multiple regressions.
© 2015 Wolters Kluwer Sørensen et al 2165older than 60 years when entering the WL, 50% died before
they received DDT. This is in accordancewith the finding of a
decreased transplantation chance among patients with high
CCI score and age older than 65 years in this study.However,
if patients older than 65 years were transplanted, there was a
significant survival benefit, although the mortality risk was
not reduced as much as in patients younger than 45 years.
In a study of 5667 renal transplant candidates older than
70 years, Rao et al20 found that among the 2438 patients
who were transplanted, the mortality risk deceased by 41%,
compared to 55% among patients older than 65 years in
the present study.
The present study demonstrates that nearly half of the pa-
tients were transplanted by either DDTor LDTwithin the first
year after entering the WL, and 71% had been transplanted
after 5 years of waiting. We found an unchanged chance of
DDTduring the study period but an increasing number of per-
formed LDT during the last 2 periods. Possible causes include
the introduction of AB0-incompatible living donor kidney
transplantation after 2006, increasing acceptance of nonre-
lated living donors (friends or partners), and the general
adoption of laparoscopic donor nephrectomises.
The excess mortality among nontransplanted patients was
mainly due to cardiovascular disease and infection. The abso-
lute risk of dying because of cancer was not different among
the transplanted patients compared with the WL patients. InFIGURE 4. Mortality (HR) according to transplant status and age
group. Multivariate analysis of 3174 patients, with patients in the age
group 18 to 44 years and never transplanted as the reference (HR= 1).
FIGURE 5. Mortality (HR) according to transplant status and CCI
group Multivariate analysis of 3174 patients, with patients having a
CCI of 2 and never transplanted as the reference (HR = 1).
2166 Transplantation ■ October 2016 ■ Volume 100 ■ Number 10 www.transplantjournal.comthis study, we only analyzed mortality due to cancer and not
the overall incidence of cancer. An increased total incidence
of cancer in kidney transplanted patients has been reported
in several studies.21-24 Thirty-two patients (19 in the WL
group and 13 of the transplanted patients) were registered
with uremia as the cause of death. Most of these will have
been due to withdrawal of active therapy, because patient
death due to lack of dialysis access is very rare in Danish clin-
ical practice. In addition, dialysis patients with serious access
problems can be listed as urgent in the WL. The increased
mortality among nontransplanted WL patients is therefore
probably due to comorbidity progression rather than dialysis
technique failure.
Time from ESRD to WL entry significantly affected both
transplant chance and patient survival. This variable could
be a measure of a more troublesome process during the
work-up program due to comorbidity and could therefore
be a prognostic factor. Transplantation with living donor
showed a relatively larger benefit compared to staying on
the WL than having DDT. However, when we analyzed only
the transplanted patients and corrected also for donor ageFIGURE 6. Cumulative incidence of dying due to infection, cancer, hear
the WL, DDT, and LDT based on univariate Cox regression with time-d
Heart, heart diseases; Vasc, vascular diseases.and donor BMI, there was an insignificant difference in mor-
tality risk in DDT compared to LDT.
We did not study either temporary or permanent with-
drawals from the WL, nor was graft failure studied. Both
temporary and permanent withdrawals from the WL are dif-
ficult to analyze in a registry study like this and could repre-
sent a bias when ignored, but also if included in the
analyses. The problem is that we do not know if the condi-
tion that had lead to thewithdrawal was related to the uremic
condition and the dialysis or would have occurred, even if the
patient had been transplanted. Removing patients from the
analysis, when they are withdrawn from the WL, would
cause bias and overestimate the effect of transplantation, be-
cause in many cases, patients are withdrawn due to illness
with an associated increased risk of death. On the other
hand, ignoring the withdrawals could also overestimate the
effect of transplantation, because some of these patients will
in fact no longer be eligible for transplantation.
The number of included patients in this study is relatively
small compared with other studies from larger countries.
However, the databases are 100% comprehensive and cover
the entire Danish population of approximately 5.5 million
people. In contrast to several other studies in this field, this
study included information about comorbidity at the time
of entering the WL in all patients. The CCI is based on the
discharge diagnoses, which are always established by a clini-
cian. In a study from 2003, Hemmelgarn et al16 found that
the original Charlson index is a valid tool to assess comorbid-
ity and predict survival in patients with ESRD. Because the
selection bias is one of the most important drawbacks in reg-
ister studies like this, information concerning comorbidity is
very valuable.
CONCLUSIONS
The percentage of transplant candidates older than
65 years increased during the study period. Poor health and
old age at the time of entering the WL reduced the chance
of being transplanted. Nevertheless, the survival benefit of
transplantation was maintained irrespective of age and
comorbidity. The increased mortality in nontransplantedts diseases, vascular diseases or other causes of death in patients on
ependent transplantation status. INF indicates infection; Ca, cancer;
© 2015 Wolters Kluwer Sørensen et al 2167patients was mainly due to increased cardiovascular and in-
fectious disease. Given that a patient can pass the standard
pretransplantation work-up program, these findings do not
support limiting access to transplantation on the basis of
age or comorbidity.
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